Key information

🔎 Fund Overview

Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell for the treatment of patients with autoimmune diseases. Its CABA platform encompasses two approaches: chimeric antigen receptor T cells for autoimmunity (CARTA) and chimeric autoantibody receptor T cells (CAART). Its product candidates include CABA-201, DSG3-CAART, DSG3/1-CAART, MuSK-CAART and PLA2R-CAART. Its lead product candidate, CABA-201, is designed to achieve transient depletion of all CD19-positive B cells following a single infusion, allowing for the elimination disease-causing B cells with subsequent repopulation by naive healthy B cells. Its lead product candidate for the CAART strategy, DSG3-CAART, is designed to enable specific cytotoxicity toward B cells autoreactive to DSG3. Its next PV product candidate, DSG3/1-CAART, is being designed to target DSG3 and/or DSG1 autoreactive B cell receptors on pathogenic B cells that cause mcPV.